A randomized, double-blind, placebo-controlled, Phase 1/2a trial protocol to assess the safety and efficacy of TAK-101 administered by microneedles in patients with celiac disease. (2022). Principles and Practice of Clinical Research, 8(3), 37-48. https://doi.org/10.21801/ppcrj.2022.83.5